Diamyd is an antigen-specific immunotherapy intended to preserve endogenous insulin production. The Food and Drug Administration (FDA) has granted Fast Track designation to Diamyd ® (recombinant human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback